🇺🇸 FDA
Patent

US 10683499

Compositions and methods for modulating TTR expression

granted A61KA61K31/7088A61K31/713

Quick answer

US patent 10683499 (Compositions and methods for modulating TTR expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
53
CPC classes
A61K, A61K31/7088, A61K31/713, A61K47/549, A61K47/59